Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Omnicell Inc Market Cap
Based on ratings from 8 stock analysts, the Omnicell Inc stock price is expected to increase by 4.98% in 12 months. This is calculated by using the average 12-month stock price forecast for Omnicell Inc. The lowest target is $30 and the highest is $61. Please note analyst price targets are not guaranteed and could be missed completely.
OMCL is a stock in Healthcare which has been forecasted to be worth $44.5 as an average. On the higher end, the forecast price is $61 USD by from Wells Fargo and on the lower end OMCL is forecasted to be $30 by Stan Berenshteyn from Wells Fargo.
These are the latest 20 analyst ratings of OMCL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anne Samuel JP Morgan | Neutral | $37 | Maintains | Aug 23, 2024 |
| Allen Lutz B of A Securities | Buy | $44 | Maintains | Aug 2, 2024 |
| Stephanie Davis Barclays | Equal-Weight | $39 | Upgrade | Aug 2, 2024 |
| Stan Berenshteyn Wells Fargo | Equal-Weight | $30 | Maintains | Aug 2, 2024 |
| Bill Sutherland Benchmark | Buy | $38 | Reiterates | Jul 15, 2024 |
| Bill Sutherland Benchmark | Buy | $38 | Reiterates | May 3, 2024 |
| Bill Sutherland Benchmark | Buy | $38 | Reiterates | Apr 30, 2024 |
| Stan Berenshteyn Wells Fargo | Equal-Weight | $26 | Maintains | Feb 9, 2024 |
| Bill Sutherland Benchmark | Buy | $38 | Maintains | Feb 9, 2024 |
| David Larsen BTIG | Neutral | Downgrade | Nov 3, 2023 | |
| Stan Berenshteyn Wells Fargo | Equal-Weight | $28 | Upgrade | Nov 3, 2023 |
| Sean Wieland Piper Sandler | Overweight | $39 | Upgrade | Nov 3, 2023 |
| Scott Schoenhaus Keybanc | Sector Weight | Downgrade | Oct 11, 2023 | |
| Bill Sutherland Benchmark | Buy | $70 | Maintains | Oct 3, 2023 |
| Stan Berenshteyn Wells Fargo | Underweight | $39 | Maintains | Sep 26, 2023 |
Keybanc | Overweight | Maintains | Aug 4, 2023 | |
Benchmark | Buy | Reiterates | Aug 2, 2023 | |
Piper Sandler | Neutral | Downgrade | Aug 2, 2023 | |
Benchmark | Buy | Reiterates | Jul 31, 2023 | |
| Stan Berenshteyn Wells Fargo | Underweight | $56 | Downgrade | Jul 20, 2023 |
When did it IPO
2001
Staff Count
3,630
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Randall A. Lipps
Market Cap
$1.95B
In 2023, OMCL generated $1.15B in revenue, which was a decrease of -11.48% from the previous year. This can be seen as a signal that OMCL's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Omnicell has appointed Nnamdi Njoku as Executive Vice President and Chief Operating Officer, a move that may influence the company's operational strategies.
Why It Matters - Nnamdi Njoku's appointment as COO may impact Omnicell's operational efficiency and strategic direction, influencing investor confidence and potential stock performance.
Wed, 11 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Omnicell is positioned for growth in future quarters due to advancements in its Autonomous Pharmacy initiative.
Why It Matters - Omnicell's progress towards the Autonomous Pharmacy goal indicates potential revenue growth, which could enhance its market position and attract investor interest.
Wed, 28 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Omnicell (OMCL) shares are rising, supported by positive earnings estimate revisions, suggesting potential continued upward movement in the near term.
Why It Matters - Rising earnings estimates for Omnicell suggest potential stock price appreciation, indicating positive market sentiment and improved financial performance, which could attract more investors.
Wed, 21 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Omnicell (OMCL) launched a subscription-based service, Central Med Automation Service, aimed at enhancing inventory visibility, scalability, and patient safety.
Why It Matters - Omnicell's new subscription service can enhance operational efficiency and safety in healthcare, potentially boosting revenues and market position, which is attractive for investors.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Omnicell has announced the launch of its Central Med Automation Service, aimed at enhancing medication management efficiency.
Why It Matters - Omnicell's launch of the Central Med Automation Service could enhance operational efficiency and reduce costs in healthcare, potentially driving revenue growth and impacting stock performance.
Thu, 15 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Omnicell will present at the 2024 Wells Fargo Healthcare Conference, providing potential insights into its business and industry trends.
Why It Matters - Omnicell's presentation at a prominent healthcare conference may signal strategic initiatives, potential partnerships, or innovation, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
